Literature DB >> 23074230

Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving p-glycoprotein at the blood-brain barrier?

Bruno Mégarbane, Hisham Alhaddad, Xavier Declèves.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23074230      PMCID： PMC3486590          DOI： 10.1128/AAC.01295-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.

Authors:  Enrico Moratti; Hamid Kashanpour; Tiziana Lombardelli; Maria Maisto
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.

Authors:  Varun Garg; Gurudatt Chandorkar; H Frank Farmer; Frances Smith; Katia Alves; Rolf P G van Heeswijk
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

3.  Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.

Authors:  Ashraf Yassen; Jingmin Kan; Erik Olofsen; Ernst Suidgeest; Albert Dahan; Meindert Danhof
Journal:  J Pharmacol Exp Ther       Date:  2007-02-05       Impact factor: 4.030

4.  Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice.

Authors:  Hisham Alhaddad; Salvatore Cisternino; Xavier Declèves; Nicolas Tournier; Joel Schlatter; Fouad Chiadmi; Patricia Risède; Maria Smirnova; Capucine Besengez; Jean-Michel Scherrmann; Frédéric J Baud; Bruno Mégarbane
Journal:  Crit Care Med       Date:  2012-12       Impact factor: 7.598

5.  Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.

Authors:  Bruno Mégarbane; Nicolas Marie; Stéphane Pirnay; Stephen W Borron; Papa N Gueye; Patricia Risède; Claire Monier; Florence Noble; Frédéric J Baud
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-16       Impact factor: 4.219

6.  Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

Authors:  Nicolas Tournier; Lucie Chevillard; Bruno Megarbane; Stéphane Pirnay; Jean-Michel Scherrmann; Xavier Declèves
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-04       Impact factor: 5.176

7.  Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; N Shimada; T Ishizaki; Y Kuroiwa
Journal:  Drug Metab Dispos       Date:  1998-08       Impact factor: 3.922

8.  Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.

Authors:  Xia Luo; Jose Trevejo; Rolf P G van Heeswijk; Frances Smith; Varun Garg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191
  8 in total
  1 in total

Review 1.  Pupillary motility: bringing neuroscience to the psychiatry clinic of the future.

Authors:  Simona Graur; Greg Siegle
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.